Healthcare provider profile · identity verified

Veena Gowra, M.D.

Family Practice · HAYWARD, CA · NPI 1518115906

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	432	160
Amlodipine Besylate	Amlodipine Besylate	249	95
Losartan Potassium	Losartan Potassium	194	74
Lisinopril	Lisinopril	187	76
Levothyroxine Sodium	Levothyroxine Sodium	167	62
Famotidine	Famotidine	119	49
Albuterol Sulfate Hfa	Albuterol Sulfate	117	59
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	101	24
Metoprolol Succinate	Metoprolol Succinate	91	35
Alendronate Sodium	Alendronate Sodium	89	32
Omeprazole	Omeprazole	86	36
Gabapentin	Gabapentin	85	44
Simvastatin	Simvastatin	85	30
Metoprolol Tartrate	Metoprolol Tartrate	83	33
Furosemide	Furosemide	81	37
Fluticasone Propionate	Fluticasone Propionate	79	33
Hydrochlorothiazide	Hydrochlorothiazide	77	34
Metformin Hcl	Metformin Hcl	72	32
Atenolol	Atenolol	69	27
Metformin Hcl Er	Metformin Hcl	63	26
Rosuvastatin Calcium	Rosuvastatin Calcium	60	22
Hydralazine Hcl	Hydralazine Hcl	53	17
Tamsulosin Hcl	Tamsulosin Hcl	50	22
Tramadol Hcl	Tramadol Hcl	50	17
Ibuprofen	Ibuprofen	49	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	47	43
Triamcinolone Acetonide	Triamcinolone Acetonide	47	34
Spiriva Respimat	Tiotropium Bromide	46	15
Alvesco	Ciclesonide	44	25
Glipizide	Glipizide	44	21
Jardiance	Empagliflozin	44	16
Oxycodone Hcl	Oxycodone Hcl	42	suppressed
Tizanidine Hcl	Tizanidine Hcl	42	19
Lovastatin	Lovastatin	38	15
Trazodone Hcl	Trazodone Hcl	37	13
Wixela Inhub	Fluticasone Propion/Salmeterol	37	14
Azithromycin	Azithromycin	36	36
Prednisone	Prednisone	36	28
Montelukast Sodium	Montelukast Sodium	35	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Sertraline Hcl	Sertraline Hcl	31	13
Duloxetine Hcl	Duloxetine Hcl	30	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	15
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	29	14
Doxycycline Monohydrate	Doxycycline Monohydrate	28	26
Ozempic	Semaglutide	28	suppressed
Potassium Chloride	Potassium Chloride	28	11
Allopurinol	Allopurinol	27	11
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Finasteride	Finasteride	27	12
Hydrocortisone	Hydrocortisone	26	18
Nystatin	Nystatin	26	13
Clopidogrel	Clopidogrel Bisulfate	25	11
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Acyclovir	Acyclovir	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Fluconazole	Fluconazole	18	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Carvedilol	Carvedilol	17	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	16	16
Meloxicam	Meloxicam	16	suppressed
Metronidazole	Metronidazole	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	11
Fluocinonide	Fluocinonide	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Latanoprost	Latanoprost	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error